Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Oct;37(10):2144–2152. doi: 10.1128/aac.37.10.2144

Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

A J Fischman 1, E Livni 1, J Babich 1, N M Alpert 1, Y Y Liu 1, E Thom 1, R Cleeland 1, B L Prosser 1, J A Correia 1, H W Strauss 1, et al.
PMCID: PMC192242  PMID: 8257137

Abstract

Positron emission tomography (PET) with [18F]fleroxacin was used to study the pharmacokinetics of fleroxacin, a new broad-spectrum fluoroquinolone, in 12 healthy volunteers (9 men and 3 women). The subjects were infused with a standard therapeutic dose of fleroxacin (400 mg) supplemented with approximately 20 mCi of [18F]fleroxacin. Serial PET images were made and blood samples were collected for 8 h, starting at the initiation of the infusion. The subjects were then treated with unlabeled drug for 3 days (400 mg/day). On the fifth day, infusion of radiolabeled drug, PET imaging, and blood collection were repeated. In most organs, there was rapid accumulation of radiolabeled drug, with stable levels achieved within 1 h after completion of the infusion. Especially high peak concentrations (in micrograms per gram) were achieved in the kidney (> 34), liver (> 25), lung (> 20), myocardium (> 19), and spleen (> 18). Peak concentrations of drug more than two times the MIC for 90% of Enterobacteriaceae strains tested (> 10-fold for most organisms) were achieved in all tissues except the brain and remained above this level for more than 6 to 8 h. The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09. Concentrations of fleroxacin in tissue were similar in males and females, before and after pretreatment with unlabeled drug.

Full text

PDF
2144

Images in this article

2146Image
on p.2146
2148Image
on p.2148

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoyama H., Inoue M., Mitsuhashi S. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):99–114. doi: 10.1093/jac/22.supplement_d.99. [DOI] [PubMed] [Google Scholar]
  2. Appelbaum P. C., Spangler S. K., Tamarree T. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin. Chemotherapy. 1988;34(1):40–45. doi: 10.1159/000238546. [DOI] [PubMed] [Google Scholar]
  3. Arakawa S., Takagi S., Matsumoto O., Kamidono S., Sengoku A., Hazama M., Yamazaki H., Hamami G., Okamoto Y., Tanaka H. [A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. Jpn J Antibiot. 1991 Jul;44(7):718–731. [PubMed] [Google Scholar]
  4. Awni W. M., Maloney J. A., Heim-Duthoy K. L. Liquid-chromatographic determination of fleroxacin in serum and urine. Clin Chem. 1988 Nov;34(11):2330–2332. [PubMed] [Google Scholar]
  5. Baba S., Mori Y., Maruo T. Penetration of fleroxacin into maxillary sinus mucosa and palatine tonsil. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):195–197. doi: 10.1093/jac/22.supplement_d.195. [DOI] [PubMed] [Google Scholar]
  6. Bannerman T. L., Wadiak D. L., Kloos W. E. Susceptibility of Staphylococcus species and subspecies to fleroxacin. Antimicrob Agents Chemother. 1991 Oct;35(10):2135–2139. doi: 10.1128/aac.35.10.2135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barrett M. S., Jones R. N., Erwin M. E., Johnson D. M., Briggs B. M. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628. Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):389–401. doi: 10.1016/0732-8893(91)90066-o. [DOI] [PubMed] [Google Scholar]
  8. Bednarczyk E. M., Green J. A., Nelson A. D., Leisure G. A., Little D., Adler L. P., Berridge M. S., Panacek E. A., Miraldi F. D. Comparison of the effect of temafloxacin, ciprofloxacin, or placebo on cerebral blood flow, glucose, and oxygen metabolism in healthy subjects by means of positron emission tomography. Clin Pharmacol Ther. 1991 Aug;50(2):165–171. doi: 10.1038/clpt.1991.121. [DOI] [PubMed] [Google Scholar]
  9. Bergström M., Litton J., Eriksson L., Bohm C., Blomqvist G. Determination of object contour from projections for attenuation correction in cranial positron emission tomography. J Comput Assist Tomogr. 1982 Apr;6(2):365–372. doi: 10.1097/00004728-198204000-00022. [DOI] [PubMed] [Google Scholar]
  10. Beskid G., Siebelist J., McGarry C. M., Cleeland R., Chan K., Keith D. D. In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin. Chemotherapy. 1990;36(2):109–116. doi: 10.1159/000238756. [DOI] [PubMed] [Google Scholar]
  11. Bowie W. R., Willetts V., Megran D. W. Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections. Antimicrob Agents Chemother. 1989 Oct;33(10):1774–1777. doi: 10.1128/aac.33.10.1774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bremner D. A., Dickie A. S., Singh K. P. In-vitro activity of fleroxacin compared with three other quinolones. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):19–23. doi: 10.1093/jac/22.supplement_d.19. [DOI] [PubMed] [Google Scholar]
  13. FOWLER J. F., YOUNG A. E. The average density of healthy lung. Am J Roentgenol Radium Ther Nucl Med. 1959 Feb;81(2):312–315. [PubMed] [Google Scholar]
  14. Fischman A. J., Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Callahan R. J., Correia J. A. Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography. Antimicrob Agents Chemother. 1992 Oct;36(10):2286–2292. doi: 10.1128/aac.36.10.2286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gardner S. F., Green J. A., Bednarczyk E. M., Nelson A. D., Leisure G., Miraldi F. An assessment of cerebral blood flow and metabolism after fleroxacin therapy. J Clin Pharmacol. 1991 Feb;31(2):151–157. doi: 10.1002/j.1552-4604.1991.tb03699.x. [DOI] [PubMed] [Google Scholar]
  16. Gasser T. C., Graversen P. H., Madsen P. O. Fleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids. Antimicrob Agents Chemother. 1987 Jul;31(7):1010–1013. doi: 10.1128/aac.31.7.1010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Georgopoulos A., Breyer S., Georgopoulos M., Mailer H., Graninger W. In-vitro activity of fleroxacin. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):25–29. doi: 10.1093/jac/22.supplement_d.25. [DOI] [PubMed] [Google Scholar]
  18. Griggs D. J., Wise R., Kirkpatrick B., Ashby J. P. The metabolism and pharmacokinetics of fleroxacin in healthy subjects. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):191–194. doi: 10.1093/jac/22.supplement_d.191. [DOI] [PubMed] [Google Scholar]
  19. Hayton W. L., Vlahov V., Bacracheva N., Viachki I., Portmann R., Muirhead G., Stoeckel K., Weidekamm E. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. Antimicrob Agents Chemother. 1990 Dec;34(12):2375–2380. doi: 10.1128/aac.34.12.2375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Heizmann P., Dell D., Eggers H., Gora R. Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1990 Apr 27;527(1):91–101. doi: 10.1016/s0378-4347(00)82086-1. [DOI] [PubMed] [Google Scholar]
  21. Jynge P., Skjetne T., Gribbestad I., Kleinbloesem C. H., Hoogkamer H. F., Antonsen O., Krane J., Bakøy O. E., Furuheim K. M., Nilsen O. G. In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. Clin Pharmacol Ther. 1990 Nov;48(5):481–489. doi: 10.1038/clpt.1990.183. [DOI] [PubMed] [Google Scholar]
  22. Kaatz G. W., Seo S. M., Barriere S. L., Albrecht L. M., Rybak M. J. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989 Apr;33(4):519–521. doi: 10.1128/aac.33.4.519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kees F., Naber K. G., Schumacher H., Grobecker H. Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue. Chemotherapy. 1988;34(6):437–443. doi: 10.1159/000238605. [DOI] [PubMed] [Google Scholar]
  24. Kosmidis J., Gargalianos P., Adamis G., Petropoulou D., Makris D. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):219–221. doi: 10.1093/jac/22.supplement_d.219. [DOI] [PubMed] [Google Scholar]
  25. Kropec A., Daschner F. In vitro activity of fleroxacin and 14 other antimicrobials against slime- and non-slime-producing Staphylococcus epidermidis. Chemotherapy. 1989;35(5):351–354. doi: 10.1159/000238694. [DOI] [PubMed] [Google Scholar]
  26. Kropec A., Daschner F. In vitro activity of fleroxacin and 6 other antimicrobials against Acinetobacter anitratus. Chemotherapy. 1989;35(5):360–362. doi: 10.1159/000238696. [DOI] [PubMed] [Google Scholar]
  27. Kusajima H., Ishikawa N., Machida M., Uchida H., Irikura T. Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys. Antimicrob Agents Chemother. 1986 Aug;30(2):304–309. doi: 10.1128/aac.30.2.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kusajima H., Ooie T., Kawahara F., Uchida H. High-performance liquid chromatographic determination of 6,8-difluoro-1-(2-fluoroethyl)-1,4- dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid and its metabolites in laboratory animals. J Chromatogr. 1986 Aug 22;381(1):137–148. doi: 10.1016/s0378-4347(00)83572-0. [DOI] [PubMed] [Google Scholar]
  29. Leibovitz E., Keren G., Shabtai M., Barzilai A., Rubinstein E. The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. J Antimicrob Chemother. 1989 Sep;24(3):375–385. doi: 10.1093/jac/24.3.375. [DOI] [PubMed] [Google Scholar]
  30. Litton J., Bergström M., Eriksson L., Bohm C., Blomqvist G., Kesselberg M. Performance study of the PC-384 positron camera system for emission tomography of the brain. J Comput Assist Tomogr. 1984 Feb;8(1):74–87. doi: 10.1097/00004728-198402000-00016. [DOI] [PubMed] [Google Scholar]
  31. Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Correia J. A., Strauss H. W., Rubin R. H. Synthesis and biodistribution of 18F-labeled fleroxacin. Nucl Med Biol. 1993 Jan;20(1):81–87. doi: 10.1016/0969-8051(93)90139-l. [DOI] [PubMed] [Google Scholar]
  32. MacDonald K. S., Cameron D. W., D'Costa L., Ndinya-Achola J. O., Plummer F. A., Ronald A. R. Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya. Antimicrob Agents Chemother. 1989 May;33(5):612–614. doi: 10.1128/aac.33.5.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Machka K., Braveny I. Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative. Eur J Clin Microbiol. 1987 Aug;6(4):482–485. doi: 10.1007/BF02013116. [DOI] [PubMed] [Google Scholar]
  34. Miller M. H., Madu A., Samathanam G., Rush D., Madu C. N., Mathisson K., Mayers M. Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. Antimicrob Agents Chemother. 1992 Jan;36(1):32–38. doi: 10.1128/aac.36.1.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Møller B. R., Kaspersen P., Mamsen A., Korsager B., Quitzau K. Fleroxacin in the treatment of uncomplicated acute cystitis in women. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):215–218. doi: 10.1093/jac/22.supplement_d.215. [DOI] [PubMed] [Google Scholar]
  36. Nakashima M., Kanamaru M., Uematsu T., Takiguchi A., Mizuno A., Itaya T., Kawahara F., Ooie T., Saito S., Uchida H. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):133–144. doi: 10.1093/jac/22.supplement_d.133. [DOI] [PubMed] [Google Scholar]
  37. Niki Y., Watanabe M., Tasaka Y., Umeki S., Soejima R. Therapeutic effect of fleroxacin against experimental pneumonia in mice. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):129–131. doi: 10.1093/jac/22.supplement_d.129. [DOI] [PubMed] [Google Scholar]
  38. Panneton A. C., Bergeron M. G., LeBel M. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. Antimicrob Agents Chemother. 1988 Oct;32(10):1515–1520. doi: 10.1128/aac.32.10.1515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Parent M., St-Laurent M., LeBel M. Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. Antimicrob Agents Chemother. 1990 Jun;34(6):1249–1253. doi: 10.1128/aac.34.6.1249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Plourde P. J., D'Costa L. J., Agoki E., Ombette J., Ndinya-Achola J. O., Slaney L. A., Ronald A. R., Plummer F. A. A randomized, double-blind study of the efficacy of fleroxacin versus trimethoprim-sulfamethoxazole in men with culture-proven chancroid. J Infect Dis. 1992 May;165(5):949–952. doi: 10.1093/infdis/165.5.949. [DOI] [PubMed] [Google Scholar]
  41. Portmann R., Hansz C., Stiglmayer R., Weidekamm E. Fleroxacin concentrations in myometrium, ovary and fallopian tube. J Antimicrob Chemother. 1989 Apr;23(4):662–664. doi: 10.1093/jac/23.4.662. [DOI] [PubMed] [Google Scholar]
  42. Pust R. A., Ackenheil-Köppe H. R., Weidner W., Meier-Ewert H. Clinical efficacy and tolerance of fleroxacin in patients with urethritis caused by Chlamydia trachomatis. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):227–230. doi: 10.1093/jac/22.supplement_d.227. [DOI] [PubMed] [Google Scholar]
  43. Rota Kops E., Herzog H., Schmid A., Holte S., Feinendegen L. E. Performance characteristics of an eight-ring whole body PET scanner. J Comput Assist Tomogr. 1990 May-Jun;14(3):437–445. doi: 10.1097/00004728-199005000-00022. [DOI] [PubMed] [Google Scholar]
  44. Saito I., Suzuki A., Yokozawa M., Ono K., Miyamura R., Hamaya O. [Bacteriological and clinical studies on fleroxacin in male gonococcal urethritis]. Hinyokika Kiyo. 1991 Jun;37(6):663–668. [PubMed] [Google Scholar]
  45. Sorgel F., Metz R., Naber K., Seelmann R., Muth P. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):155–167. doi: 10.1093/jac/22.supplement_d.155. [DOI] [PubMed] [Google Scholar]
  46. Stuck A. E., Kim D. K., Frey F. J. Fleroxacin clinical pharmacokinetics. Clin Pharmacokinet. 1992 Feb;22(2):116–131. doi: 10.2165/00003088-199222020-00003. [DOI] [PubMed] [Google Scholar]
  47. Sörgel F., Kinzig M. Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition. Am J Med. 1993 Mar 22;94(3A):44S–55S. [PubMed] [Google Scholar]
  48. Sörgel F., Seelmann R., Naber K., Metz R., Muth P. Metabolism of fleroxacin in man. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):169–178. doi: 10.1093/jac/22.supplement_d.169. [DOI] [PubMed] [Google Scholar]
  49. Weidekamm E., Portmann R., Suter K., Partos C., Dell D., Lücker P. W. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrob Agents Chemother. 1987 Dec;31(12):1909–1914. doi: 10.1128/aac.31.12.1909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wise R., Honeybourne D., Andrews J. M., Ashby J. P. The penetration of fleroxacin into bronchial mucosa. J Antimicrob Chemother. 1988 Aug;22(2):203–206. doi: 10.1093/jac/22.2.203. [DOI] [PubMed] [Google Scholar]
  51. Wise R., Kirkpatrick B., Ashby J., Griggs D. J. Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. Antimicrob Agents Chemother. 1987 Feb;31(2):161–163. doi: 10.1128/aac.31.2.161. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES